<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703573</url>
  </required_header>
  <id_info>
    <org_study_id>0721D1424</org_study_id>
    <nct_id>NCT00703573</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of 2 Doses of S-777469 (400 mg BID and 800 mg BID) in Patients With Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of 2 doses of S-777469 in&#xD;
      patients with atopic dermatitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of S-777469 was assessed by Physician's Global Assessment (PGA) and Numerical Rating Scale (NRS)</measure>
    <time_frame>Change from baseline to 12 weeks</time_frame>
    <description>Physician's Global Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety was assessed by repeated clinical evaluation and evaluation of treatment-emergent adverse events. It included vital signs, medical history, concomitant medications, physical examination, 12-lead ECGs, and standard clinical laboratory safety tests</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Safety, determined by Adverse event frequency and changes in laboratory values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy was assessed by PGA, NRS, Behavioral Rating Scale, Eczema Area and Severity Index Score, Investigator panel treatment-blind comparative review ratings of digital photography of affected areas, and Thymus and Activation-Regulated Chemokine</measure>
    <time_frame>Changes from baseline to various pre-defined time-points during the 12 week study</time_frame>
    <description>Assessment of PGA, NRS, Behavioral Rating Scale, Eczema Area and Severity Index Score, Investigator panel treatment-blind comparative review ratings of digital photography of affected areas, and Thymus and Activation-Regulated Chemokine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis of the concentration of unchanged parent drug (S-777469) in trough samples</measure>
    <time_frame>From Baseline during Week 1</time_frame>
    <description>The concentration of S-777469 will be evaluated to determine when steady state is achieved</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">209</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID (four tablets of placebo BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-777469 400 mg</intervention_name>
    <description>S-777469 400 mg BID</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-777469 800 mg</intervention_name>
    <description>S-777469 800 mg BID</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Inclusion Criteria:&#xD;
&#xD;
        Each patient must meet all of the following inclusion criteria to be screened and enrolled&#xD;
        into the single-blind period:&#xD;
&#xD;
          -  Males or females between 18 and 65 years of age at the time of obtaining the written&#xD;
             informed consent&#xD;
&#xD;
          -  Patient understands the study procedures and agrees to participate in the study by&#xD;
             giving written informed consent&#xD;
&#xD;
          -  Patient agrees to allow digital photographs of atopic dermatitis (AD)-affected target&#xD;
             areas during the study&#xD;
&#xD;
          -  Patient satisfies the diagnostic criteria for AD as defined by the criteria of Hanifin&#xD;
             and Rajka (Acta Derm Venereol.1980;92[suppl]:44-47; J Am Acad&#xD;
             Dermatol.2003;49[6]:1088-1095), as follows:&#xD;
&#xD;
        Must have 3 or more basic features:&#xD;
&#xD;
          -  Pruritis&#xD;
&#xD;
          -  Typical morphology and distribution: flexural lichenification or linearity&#xD;
&#xD;
          -  Chronic or chronically relapsing dermatitis&#xD;
&#xD;
          -  Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)&#xD;
&#xD;
        Plus 3 or more minor features:&#xD;
&#xD;
          -  Xerosis&#xD;
&#xD;
          -  Ichthyosis/palmar hyperlinearity/keratosis pilaris&#xD;
&#xD;
          -  Early age of onset&#xD;
&#xD;
          -  Tendency toward cutaneous infections (esp. Staphylococcus aureus and Herpes simplex)&#xD;
             /impaired cell-mediated immunity&#xD;
&#xD;
          -  Tendency toward non-specific hand or foot dermatitis&#xD;
&#xD;
          -  Nipple eczema&#xD;
&#xD;
          -  Cheilitis&#xD;
&#xD;
          -  Recurrent conjunctivitis&#xD;
&#xD;
          -  Dennie-Morgan infraorbital fold&#xD;
&#xD;
          -  Keratoconus&#xD;
&#xD;
          -  Anterior subcapsular cataracts&#xD;
&#xD;
          -  Orbital darkening&#xD;
&#xD;
          -  Facial pallor/facial erythema&#xD;
&#xD;
          -  Pityriasis alba&#xD;
&#xD;
          -  Anterior neck folds&#xD;
&#xD;
          -  Itch when sweating&#xD;
&#xD;
          -  Intolerance to wool and lipid solvents&#xD;
&#xD;
          -  Perifollicular accentuation&#xD;
&#xD;
          -  Food intolerance&#xD;
&#xD;
          -  Course influenced by environmental/emotional factors&#xD;
&#xD;
          -  White dermographism/delayed blanch&#xD;
&#xD;
          -  Immediate (type I) skin test reactivity (Provide test results within one year of&#xD;
             Screening date.)&#xD;
&#xD;
          -  Elevated serum IgE.&#xD;
&#xD;
               -  Patient has negative laboratory results for hepatitis B surface antigen and IgG&#xD;
                  anti- Hepatitis B core, hepatitis C virus antibodies, and human immunodeficiency&#xD;
                  virus (HIV) antibody tests at screening&#xD;
&#xD;
               -  Serum creatinine and blood urea nitrogen are in the normal range at screening&#xD;
&#xD;
               -  Female patients of child bearing potential must have a negative pregnancy test at&#xD;
                  screening and Day-14&#xD;
&#xD;
               -  Patient has a negative screen for drugs of abuse at screening&#xD;
&#xD;
               -  Patient does not have a history or clinical manifestations of significant&#xD;
                  metabolic, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
                  gastrointestinal or urological disease&#xD;
&#xD;
               -  Patient does not have liver function test results &gt;1.25 the upper limit of normal&#xD;
                  NOTE: Under no circumstances should a patient who did not qualify regarding liver&#xD;
                  function tests (alanine aminotransferase [ALT] and/or aspartate aminotransferase&#xD;
                  [AST]) be re-screened and/or re-qualified&#xD;
&#xD;
               -  Patient does not have QTc &gt; 450 (males) or &gt; 470 (females) at screening&#xD;
&#xD;
        Randomization Inclusion Criteria:&#xD;
&#xD;
        Patients eligible to be randomized to double-blind treatment must satisfy all of the&#xD;
        following inclusion criteria:&#xD;
&#xD;
          -  Patient has all of the following at the end of the single-blind period (Day 1, just&#xD;
             before randomization to study drug):&#xD;
&#xD;
               -  Physician's Global Assessment (PGA) ≥ 2 but ≤ 4.&#xD;
&#xD;
               -  The average of the scores recorded from the evening of Day -3 to the morning of&#xD;
                  Day 1 (Baseline value) of the Numerical Rating Scale (NRS) is ≥ 4.&#xD;
&#xD;
               -  The average of the scores recorded from the evening of Day -3 to the morning of&#xD;
                  Day 1 (Baseline value) of the Behavior Rating Scale (BRS) is ≥ 2&#xD;
&#xD;
          -  Patient has negative laboratory results for hepatitis B surface antigen, IgE&#xD;
             anti-Hepatitis B core, hepatitis C virus antibodies, and HIV antibody tests at&#xD;
             screening&#xD;
&#xD;
          -  Female patients of child bearing potential must have a negative pregnancy test at&#xD;
             screening, single-blind period (Day-14) and baseline (Day 1)&#xD;
&#xD;
          -  Serum creatinine and blood urea nitrogen are in the normal range at screening&#xD;
&#xD;
          -  Patient has negative screen for drugs of abuse at screening and single-blind (Day-14)&#xD;
&#xD;
          -  Use of adequate birth control by men and women, if of reproductive potential and&#xD;
             sexually active. Adequate birth control is defined as agreement to consistently&#xD;
             practice an effective and accepted method of contraception throughout the duration of&#xD;
             the study and for 2 weeks after the last dose of study drug&#xD;
&#xD;
               -  For females, adequate birth control methods will be defined as: hormonal&#xD;
                  contraceptives, intrauterine device or double barrier contraception, i.e., condom&#xD;
                  + diaphragm, condom or diaphragm + spermicidal gel or foam&#xD;
&#xD;
               -  For males adequate birth control methods will be defined as double barrier&#xD;
                  contraception, i.e., condom + diaphragm, condom or diaphragm + spermicidal gel or&#xD;
                  foam&#xD;
&#xD;
               -  For females, menopause is defined as one year without menses; if in question, a&#xD;
                  follicle-stimulating hormone of &gt;40 U/ml must be documented. Hysterectomy,&#xD;
                  bilateral oophorectomy, or bilateral tubal ligation must be documented, as&#xD;
                  applicable&#xD;
&#xD;
          -  Patient has not used any treatments for AD prior to Day 1, using the following time&#xD;
             periods:&#xD;
&#xD;
               -  Systemic (inhaled, oral, suppository or immediate release injectable, depot or&#xD;
                  sustained-release injectable) corticosteroids, cytostatic drugs, or other&#xD;
                  immunosuppressant drugs: 5 weeks prior to Day 1&#xD;
&#xD;
               -  Topical immunosuppressant drugs: 4 weeks prior to Day 1&#xD;
&#xD;
               -  Phototherapy, specific desensitization therapy, nonspecific disease-modulating&#xD;
                  therapy and elimination diet therapy: 4 weeks prior to Day 1&#xD;
&#xD;
               -  Any drugs that are known inhibitors or inducers of Cytochrome P450 isozyme&#xD;
                  cytochrome CYP2C9: 2 weeks prior to Day 1&#xD;
&#xD;
               -  Systemic antibiotics: 4 weeks prior to Day 1&#xD;
&#xD;
               -  Topical steroids or tar preparations: 2 weeks prior to Day 1&#xD;
&#xD;
               -  Antihistamines, histamine-added γ-globulin preparations, desensitization therapy,&#xD;
                  or other nonspecific disease-modifying therapies: 2 weeks prior to Day 1&#xD;
&#xD;
               -  Herbal preparation, cosmetic or emollient preparations other than those issued&#xD;
                  during the screening and single-blind periods: 2 weeks prior to Day 1. Use of&#xD;
                  cosmetic make-up will be allowed&#xD;
&#xD;
               -  Acetaminophen, acetaminophen-containing products, or non-steroidal&#xD;
                  anti-inflammatories: 2 weeks prior to Day 1&#xD;
&#xD;
               -  Any other investigational drug or device within 8 weeks prior to Day 1&#xD;
&#xD;
          -  Patient is willing to completely avoid the use of any prescription or nonprescription&#xD;
             treatments for AD , including over-the-counter drugs or any topical preparations,&#xD;
             other than those topical emollient preparations provided by the study site during the&#xD;
             screening period and thereafter, as needed. Use of hormone replacement therapy (for&#xD;
             postmenopausal females) and/or use of hormonal contraceptive(s), intrauterine device,&#xD;
             or double barrier contraception, i.e., condom + diaphragm, condom or diaphragm +&#xD;
             spermicidal gel or foam will be allowed. Use of topical antibiotics will be allowed&#xD;
             during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients satisfying any of the following exclusion criteria are not eligible for enrollment&#xD;
        into the double-blind treatment period:&#xD;
&#xD;
          -  Patient is under the age of legal consent, is mentally or legally incapacitated and/or&#xD;
             has significant emotional problems at the time of study entry&#xD;
&#xD;
          -  Patient has an active dermatologic condition other than AD which may confound the&#xD;
             diagnosis or evaluation of AD, such as scabies, allergic contact dermatitis,&#xD;
             seborrheic dermatitis, cutaneous lymphoma, or psoriasis&#xD;
&#xD;
          -  Patient has a history of malignancy not in remission for &gt;5 years, with the exception&#xD;
             of cutaneous basal cell carcinoma and cutaneous squamous cell carcinoma&#xD;
&#xD;
          -  Presence of comorbid conditions that would preclude participation in the study,&#xD;
             including:&#xD;
&#xD;
               -  Immune compromised state, including recent chemotherapy, immunotherapy, or organ&#xD;
                  transplant&#xD;
&#xD;
               -  History or clinical manifestations of significant metabolic, hepatic, renal,&#xD;
                  hematological, pulmonary, cardiovascular, gastrointestinal or urological disease&#xD;
&#xD;
               -  Signs and symptoms of eczema herpeticum within the preceding 12 months or&#xD;
                  cellulitis within preceding 3 months&#xD;
&#xD;
               -  Positive results for HIV infection at screening&#xD;
&#xD;
               -  History or clinical manifestations of significant neurological (e.g., epilepsy)&#xD;
                  or psychiatric disorders (e.g., history of suicide attempt; history of&#xD;
                  psychiatric episodes resulting in hospitalization)&#xD;
&#xD;
               -  An active intercurrent infection&#xD;
&#xD;
               -  History of clinically significant hypersensitivity, anaphylaxis, or allergies to&#xD;
                  any drug compound, which resulted in a severe adverse event&#xD;
&#xD;
               -  Liver function tests (ALT, AST) &gt;1.25 times the upper limit of normal at&#xD;
                  Screening. (refer to Covance Lab Manual for reference ranges) Note: Under no&#xD;
                  circumstances should a patient who did not qualify regarding liver function tests&#xD;
                  (ALT and/or AST) be re-screened and/or re-qualified&#xD;
&#xD;
          -  Patient has any acute or chronic condition or prior therapy that, in the opinion of&#xD;
             the Investigator, would limit the patient's ability to complete and/or participate in&#xD;
             this clinical study or otherwise would make the patient unsuitable for this study&#xD;
&#xD;
          -  Patient has a history of drug abuse within 1 year prior to Day 1&#xD;
&#xD;
          -  Patient consumes excess amounts of alcohol, defined as exceeding an average of 14&#xD;
             drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard&#xD;
             liquor, or any combination of them) within 2 months prior to Day -14 (beginning of&#xD;
             single-blind period) or is unwilling to comply with the restricted use of alcohol (as&#xD;
             defined above, no more than 14 drinks/week) from screening, throughout the study, and&#xD;
             until study completion (follow-up visit).&#xD;
&#xD;
          -  Patient uses any prohibited concomitant medications at any time during the study&#xD;
&#xD;
          -  Patient is pregnant or lactating or intends to become pregnant or, in the case of a&#xD;
             male patient, intends to father a child during the study period and for 2 weeks after&#xD;
             the last dose of study medication&#xD;
&#xD;
          -  Patient has poor peripheral venous access that may limit blood sampling for clinical&#xD;
             laboratory or pharmacokinetic analysis&#xD;
&#xD;
          -  Patient has participated in any other investigational study drug or device trial in&#xD;
             which receipt of an investigational study drug or device occurred within 8 weeks prior&#xD;
             to Day 1&#xD;
&#xD;
          -  Prior exposure to S-777469&#xD;
&#xD;
          -  Any reason which, in the opinion of the Investigator, interferes with the ability of&#xD;
             the patient to participate in or complete the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>973239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 20, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <disposition_first_submitted>April 26, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 1, 2018</disposition_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

